Updates are available Correction dated 2022-12-23
Click to view Correction: https://doi.org/10.1007/s00401-022-02534-0
-
Authors
Hart de Ruyter, Frederique J. https://orcid.org/0000-0001-5023-4882
Morrema, Tjado H. J.
den Haan, Jurre
,
Twisk, Jos W. R.
de Boer, Johannes F.
Scheltens, Philip
Boon, Baayla D. C.
Thal, Dietmar R.
Rozemuller, Annemieke J.
Verbraak, Frank D.
Bouwman, Femke H.
Hoozemans, Jeroen J. M.
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (P18-26 Project 5)
- License Information
-
More Information
Article History
Received: 3 June 2022
Revised: 22 November 2022
Accepted: 22 November 2022
First Online: 8 December 2022
Change Date: 23 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00401-022-02534-0
Declarations
:
: F.J. Hart de Ruyter reports no competing interests; T.H.J. Morrema reports no competing interests; Dr. J. den Haan reports no competing interests; Prof. dr. J.W.R. Twisk reports no competing interests; Prof. dr. J.F. de Boer has acquired grant support (for the institution; Department of Physics, VU) from the Dutch Research Council (NWO) and from industry (Thorlabs, ASML, Heidelberg Engineering). He has received royalties related to IP on OCT technologies and semiconductor metrology. He has acted as an expert witness for a UK based law firm; Prof. Dr. P. Scheltens has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell and Green Valley. Within his university affiliation he is global PI of the phase 1b study of AC Immune, Phase 2b study with FUJI-film/Toyama and phase 2 study of UCB and phase 1 study with ImmunoBrain Checkpoint. He is chair of the EU steering committee of the phase 2b program of Vivoryon, the phase 2b study of Novartis Cardiology and co-chair of the phase 3 study with NOVO-Nordisk. He is also an employee of EQT Life Sciences (formerly LSP); Dr. B.D.C. Boon is supported by a research fellowship awarded by Alzheimer Nederland (#WE.15-2019-13); Prof. dr. D.R. Thal received speaker honorarium from Novartis Pharma Basel (Switzerland) and Biogen (USA), travel reimbursement from GE-Healthcare (UK), and UCB (Belgium), and collaborated with GE-Healthcare (UK), Novartis Pharma Basel (Switzerland), Probiodrug (Germany), and Janssen Pharmaceutical Companies (Belgium). He receives grants from Fonds Wetenschappelijk Onderzoek Vlaanderen (Belgium; FWO- G0F8516N, G065721N) and the Stichting Alzheimer Onderzoek (Belgium; SAO-FRA 2020/017); Prof. dr. A.J. Rozemuller reports no competing interests; Dr. F.D. Verbraak reports no competing interests; Dr. F. Bouwman performs contract research for Optina Dx and Optos, she has been an invited speaker at Roche and has been invited for expert testimony at Biogen. All funding is paid to her institution; Dr. J.J.M. Hoozemans received grants from the Dutch Research Council (ZonMW) and, Alzheimer Netherlands, performed contract research or received grants from Merck, ONO Pharmaceuticals, Janssen Prevention Center, DiscovericBio, AxonNeurosciences, Roche, Genentech, Promis, Denali, FirstBiotherapeutics, and Ensol Biosciences. All payments were made to the institution. Dr. J.J.M. Hoozemans participates in the scientific advisory board of Alzheimer Netherlands and is editor-in-chief for Acta Neuropathologica Communications.
: Donors signed informed consent for brain and eye autopsy and use of brain and retinal tissue and medical records for research prior to death. This study was approved by the ethical committee of the VU University Medical Center Amsterdam (VUmc).
